SWTX (SpringWorks Therapeutics) Earnings growth in current year

The annual EPS growth ratio demonstrates earnings per share dynamics, with the 18.70 metric serving as the target level. SpringWorks Therapeutics (SWTX) possesses exceptional macro-resilience, as demand for oncology drugs remains independent of economic cycles. The company is implementing breakthrough enzyme-blocking methods for rare pathologies. Currently, the brand is scaling Ogsiveo sales while expanding its portfolio of targeted therapies.

SWTX (SpringWorks Therapeutics, Inc.) Earnings growth in current year history from 07/04/2022 to 07/12/2025

Comprehensive metric breakdowns and analytics for SpringWorks Therapeutics (SWTX)

- share price and expert price forecast:

Price SpringWorks Therapeutics Inc.|SWTX - Analyst Consensus Forecast

- business market valuation indicators:

Market Capitalization SpringWorks Therapeutics, Inc|SWTX - Total Company Value

- book capitalization data:

Accounting Value of a Share SpringWorks Therapeutics|SWTX - Book Capitalization|Market Value to Equity Ratio springworkstx.com|SWTX - Company Total Assets

- debt and liquidity details:

Debt to Capital SpringWorks Therapeutics|SWTX - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio springworkstx.com|SWTX - Company Aggregate Debts|Debts to Book Value SpringWorks Therapeutics, Inc|SWTX - Company Long-Term Debts|Company Short-Term Indebtedness SpringWorks Therapeutics|Intermediate Coverage Ratio springworkstx.com

- net income and valuation multiples indicators:

SWTX - Net Income|Future Net Profit SpringWorks Therapeutics|SWTX - P/E Multiple|Future Price to Earnings Multiple SpringWorks Therapeutics, Inc|SWTX - PEG Multiple|Company Value to EBITDA SpringWorks Therapeutics, Inc|SWTX - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year SpringWorks Therapeutics|SWTX - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth springworkstx.com|SWTX - Earnings per share growth in current year|Net earnings per share change forecast for next year SpringWorks Therapeutics

Fundamental valuation:SWTX SpringWorks Therapeutics Inc.

Signature product of SpringWorks Therapeutics, Inc

The eps_yy_co metric measures the annual growth rate of earnings per share, capturing the percentage deviation of current results from the same period last year. Analyzing EPS YoY volatility allows for the identification of operational stabilization phases or margin compression, which is critical for assessing cash flow sustainability. For SpringWorks Therapeutics (SWTX), this metric reflects the financial impact of Ogsiveo's commercialization and the scaling of its oncology portfolio.

Direct competitors